Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuneRegen product to undergo anti-microbial evaluation
Under the terms of the agreement, the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes for Health (NIH), will fund and conduct
Under the terms of the agreement, the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes for Health (NIH), will fund and conduct
The purpose of the transaction is to explore Durolane and other products for the management of osteoarthritis (OA) in joints and to explore other orthopedic uses and diseases.
The closure follows the US company’s acquisition of Agis. Since the takeover, Perrigo has been pursuing opportunities to integrate both businesses and streamline production. The global healthcare supplier
Spherics has developed advanced oral systems based on the application of proprietary bioadhesive polymers to oral dosage forms. These broadly enabling technologies have potential to expand the therapeutic
XL880 is a small molecule inhibitor of the receptor tyrosine kinases (RTKs) involved in tumor cell growth, migration and angiogenesis, including MET and VEGFR. A multi-center open-label phase
NVA237 is a collaborative product of Sosei and Vectura that is being developed and commercialized by Novartis, both as a monotherapy and in combination with its once-daily bronchodilator
The companies will collaborate on the development of the product and co-commercialize Hematide in the US, while Takeda will hold an exclusive license to develop and commercialize outside
Under the terms of the proposal, Pliva's shareholders would receive approximately HRK705 ($122) for each share they hold in the company. The offer represents a premium of 24%
Under the terms of the agreement, Aurigene will contribute its expertise in discovery and in-vivo optimisation of lead compounds, whilst drug development expertise will be provided by Debiopharm.
Cephalon said that it will conduct a complete analysis of the data to assist in its evaluation of future clinical development plans for Gabitril in other therapeutic areas.